The American Cancer Society estimates that there will be 102,480 new cases of colon cancer diagnosed in 2013, with hereditary colon cancer syndromes accounting for approximately 10 percent of those cases. It’s important to identify the hereditary colon cancer cases because of the important ramifications for the affected individual and their family members.
Mayo Medical Laboratories is pleased to announce the availability of our Hereditary Colon Cancer Multi-Gene Panel. This panel uses next generation sequencing (NGS), array comparative genomic hybridization (aCGH), and other technologies to evaluate for germline mutations in 17 genes known to be associated with an increased risk for colon cancer development.
In this video, Mayo Clinic gastroenterologist and celiac disease expert Joseph Murray, M.D., discusses a recent article published in Alimentary Pharmacology & Therapeutics that examined the effectiveness of larazotide acetate as an alternative treatment for celiac disease.
CDG can present with a broad clinical spectrum from developmental delay to multiorgan involvement (eg, liver disease, developmental delay, failure to thrive, chronic diarrhea, abnormal subcutaneous fat distribution, retinitis pigmentosa, cutis laxa, etc.).
A copy number + single nucleotide polymorphism (SNP) chromosomal microarray test is now available from Mayo Medical Laboratories. Read more for full details, including the advantages of a CMA copy number + SNP test.
Historically, Friedreich ataxia has been diagnosed by DNA-based testing. However, a molecular-based analysis does not effectively monitor treatment, is not amenable to multiplexing with other disease analytes, nor can it be efficiently utilized for population screening.
Lymphomas are among the most complex diseases to recognize and diagnose because they are pathologically complex, with features that overlap with reactive and inflammatory conditions and other nonhematologic malignancies. Criteria for lymphoma diagnosis rely on morphology and a variety of ancillary studies, including phenotype and genetic features.
Heart failure is a complex cardiovascular disorder with a variety of etiologies and heterogeneity with respect to the clinical presentation of the patient. New biomarkers are available that can assist in the prognosis for patients already diagnosed with heart failure, and can aid in risk stratification, earlier detection of treatment failure, and therapeutic targets.
The genetic aberrations present in multiple myeloma cells play a significant role in the risk stratification and therapeutic approach in multiple myeloma patients. Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART ) represents a consensus opinion on the utilization and assessment of these genetic markers in multiple myeloma.